期刊
VACCINE
卷 27, 期 8, 页码 1216-1229出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.12.014
关键词
Tularemia vaccine; Francisella tularensis; Listeria monocytogenes; Biodefense
资金
- U.S. Army Medical Research and Materiel Command [DAMD17-03-1-0052]
- National Institutes of Health [AI065359, HL07700]
Fransicella tularensis, the causative agent Of tularemia, is in the top category (Category A) of potential agents of bioterrorism. To develop a safer vaccine against aerosolized F. tularensis, we have employed an attenuated Listeria monocytogenes, which shares with F tularensis an intracellular and extraphagosomal lifestyle, as a delivery vehicle for F. tularensis antigens. We constructed recombinant L. monocytogenes (rLm) vaccines stably expressing seven F. tularensis proteins including IglC (rLm/iglC), and tested their immunogenicity and protective efficacy against lethal E tularensis challenge in mice. Mice immunized intradermally with rLm/iglC developed significant cellular immune responses to F tularensis iglC as evidenced by lymphocyte Proliferation and CD4+ and CD8+ T-cell intracellular expression of interferon gamma. Moreover, mice immunized With rLm/iglC were protected against lethal challenge with F tularensis LVS administered by the intranasal route, a route chosen to mimic airborne infection, and, most importantly, against aerosol challenge with the highly Virulent Type A F tularensis SchuS4 strain. (C) 2008 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据